A phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.
Name:
s00280-018-3558-z.pdf
Size:
823.6Kb
Format:
PDF
Description:
Full text, Open Access article
Authors
Dean, Emma JBanerji, U
Schellens, J
Krebs, Matthew G
Jimenez, B
van Brummelen, E
Bailey, C
Casson, E
Cripps, D
Cullberg, M
Evans, S
Foxley, A
Lindemann, J
Rugman, P
Taylor, N
Turner, G
Yates, J
Lawrence, P
Affiliation
The Christie NHS Foundation Trust, The University of Manchester, Manchester, UKIssue Date
2018-03-14
Metadata
Show full item recordAbstract
AZD5363 is a potent pan-AKT inhibitor originally formulated as a capsule; a tablet was developed for patient convenience and manufacturing ease. This study assessed the PK comparability of both formulations (Part A) and the effect of food (Part B) on the PK/safety of the tablet.Citation
A phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK. 2018, Cancer Chemother PharmacolJournal
Cancer Chemotherapy and PharmacologyDOI
10.1007/s00280-018-3558-zPubMed ID
29541803Type
ArticleLanguage
enISSN
1432-0843ae974a485f413a2113503eed53cd6c53
10.1007/s00280-018-3558-z
Scopus Count
Collections
Related articles
- A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
- Authors: Falchook G, Patnaik A, Richardson DL, Harvey RD, Sharma MR, Hafez N, Hamilton E, Piha-Paul SA, Barve M, Wise-Draper T, Patel MR, Dowlati A, Pascuzzo J, Tang SC, Faltermeier C, Malinowska IA, Shtessel L, Striha A, Potocka E
- Issue date: 2024 Mar
- Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1).
- Authors: Aslanis V, Abd-Elaziz K, Slack RJ, Brinch A, Gravelle L, Morley W, Phung D, Herman K, Holyer I, Poulsen KK, Dogterom P, Tantawi S, Zetterberg FR, Jacoby B, Schambye H, Lindmark B
- Issue date: 2024 Nov
- Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
- Authors: Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Grève J, Lolkema MP, Soetekouw P, Mau-Sørensen M, Nielsen D, Spicer J, Fielding A, So K, Bannister W, Molife LR
- Issue date: 2015 Oct
- Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.
- Authors: Krishna G, Ma L, Martinho M, O'Mara E
- Issue date: 2012 Aug
- Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.
- Authors: Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel MR, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Lockhart AC, Tan E, Yang S, Carlson G, Scott JW, Sharma S
- Issue date: 2016 Nov